echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Idiopathic narcolepsy drug Xywav oral solution receives priority review by the U.S. FDA

    Idiopathic narcolepsy drug Xywav oral solution receives priority review by the U.S. FDA

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Recently, Jazz Pharmaceuticals announced that the FDA has accepted Xywav oral solution for the treatment of adult patients with idiopathic narcolepsy as a supplementary new drug application for substantive review.
    The FDA granted the sNDA a priority review, and has designated the "Prescription Drug User Fees Act" (PDUFA) target action date of August 2, 2021.

    If approved, Xywav will be the first and only drug in the United States to treat adult patients with IH.
    In July 2020, Xywav was approved by the US FDA for the treatment of cataplexy or excessive daytime sleepiness (EDS) in narcolepsy (narcolepsy) patients 7 years and older.

    IH is a chronic neurological disease characterized by excessive sleepiness, uncontrollable sleep requirements, or daytime sleepiness that lasts for at least 3 months, even when sleep is adequate or prolonged at night.
    According to US insurance claims data, there are more than 37,000 adult patients diagnosed with IH, but there may be more undiagnosed.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.